Cargando…

The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells

BACKGROUND: Chemotherapy resistance is the main cause of the marginal clinical benefit of platinum-based chemotherapy and tyrosine kinase inhibitors in advanced non-small-cell lung cancer (NSCLC). Thus, the identification of new therapeutic agents that can enhance the sensitivity of these drugs is o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al-Keilani, Maha S, Alzoubi, Karem H, Jaradat, Saied A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186900/ https://www.ncbi.nlm.nih.gov/pubmed/30349406 http://dx.doi.org/10.2147/CPAA.S174074

Ejemplares similares

Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
por: Li, Yang-Ling, et al.
Publicado: (2018)

Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC
por: Pan, Chi, et al.
Publicado: (2020)

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
por: Li, Jun, et al.
Publicado: (2019)

Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2005)

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
por: Pao, William, et al.
Publicado: (2005)

Combination Erlotinib-Cisplatin and Atg3-Mediated Autophagy in Erlotinib Resistant Lung Cancer
por: Lee, Jasmine G., et al.
Publicado: (2012)

Correction: Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2012)

Pramlintide, an antidiabetic, is antineoplastic in colorectal cancer and synergizes with conventional chemotherapy
por: Al-Keilani, Maha S, et al.
Publicado: (2018)

Clinical and Experimental Applications of Sodium Phenylbutyrate
por: Iannitti, Tommaso, et al.
Publicado: (2012)

Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases
por: Arakawa, Nobuhito, et al.
Publicado: (2013)

Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis
por: Zou, Bin, et al.
Publicado: (2018)

Pilot study of radiofrequency hyperthermia in combination with gefitinib in gefitinib‐effective patients with advanced NSCLC
por: Qin, Yijia, et al.
Publicado: (2016)

Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib
por: Nagano, Tatsuya, et al.
Publicado: (2011)

Enhanced antiproliferative and apoptotic response to combined treatment of γ-tocotrienol with erlotinib or gefitinib in mammary tumor cells
por: Bachawal, Sunitha V, et al.
Publicado: (2010)

Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
por: He, Qihua, et al.
Publicado: (2021)

Treatment with gefitinib after erlotinib-induced liver injury: a case report
por: Nakatomi, Katsumi, et al.
Publicado: (2011)

Erlotinib and gefitinib treatments of the lung cancer in an elderly patient result in gastrointestinal bleeding
por: Bai, Hongmei, et al.
Publicado: (2013)

Efficacy of gefitinib or erlotinib in patients with squamous cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2013)

Case of Proteinuria, Worsening Hypertension, and Glomerular Endotheliosis With Erlotinib and Gefitinib
por: Latcha, Sheron, et al.
Publicado: (2018)

Combination phenylbutyrate/gemcitabine therapy effectively inhibits in vitro and in vivo growth of NSCLC by intrinsic apoptotic pathways
por: Schniewind, Bodo, et al.
Publicado: (2006)

ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC
por: Zhao, Hongbo, et al.
Publicado: (2018)

Brain metastasis effectively treated with erlotinib following the acquisition of resistance to gefitinib: a case report
por: Ohara, Sayaka, et al.
Publicado: (2014)

A Patient with MSUD: Acute Management with Sodium Phenylacetate/Sodium Benzoate and Sodium Phenylbutyrate
por: Köse, Melis, et al.
Publicado: (2017)

Profile of sodium phenylbutyrate granules for the treatment of urea-cycle disorders: patient perspectives
por: Peña-Quintana, Luis, et al.
Publicado: (2017)

Aspartames Alter Pharmacokinetics Parameters of Erlotinib and Gefitinib and Elevate Liver Enzymes in Wistar Rats
por: AlRasheed, Hajer, et al.
Publicado: (2022)

Effect of sodium 4-phenylbutyrate on Clenbuterol-mediated muscle growth
por: Brown, David M., et al.
Publicado: (2018)

Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC
por: Bahce, Idris, et al.
Publicado: (2016)

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
por: Pao, William, et al.
Publicado: (2005)

Metabolic Glycoengineering Sensitizes Drug-Resistant Pancreatic Cancer Cells to Tyrosine Kinase Inhibitors Erlotinib and Gefitinib
por: Mathew, Mohit P., et al.
Publicado: (2015)

TXNIP mediates the differential responses of A549 cells to sodium butyrate and sodium 4‐phenylbutyrate treatment
por: Jin, Xuefang, et al.
Publicado: (2016)

Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab
por: Villalobos, Matthias, et al.
Publicado: (2019)

Sodium 4-phenylbutyrate suppresses the development of dextran sulfate sodium-induced colitis in mice
por: ONO, KAZUHIKO, et al.
Publicado: (2014)

Efficacy of orally administered sodium benzoate and sodium phenylbutyrate in dogs with congenital portosystemic shunts
por: van Straten, Giora, et al.
Publicado: (2019)

Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
por: Wong, Matthew K., et al.
Publicado: (2009)

Synergistic Effect of Afatinib with Su11274 in Non-Small Cell Lung Cancer Cells Resistant to Gefitinib or Erlotinib
por: Chen, Gang, et al.
Publicado: (2013)

Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
por: Emery, Ivette F, et al.
Publicado: (2009)

Tyrosine kinase inhibitors show different anti-brain metastases efficacy in NSCLC: A direct comparative analysis of icotinib, gefitinib, and erlotinib in a nude mouse model
por: Tan, Jianlong, et al.
Publicado: (2017)

Effect of Gefitinib Combined with Chemotherapy in Patients with Advanced NSCLC: A Retrospective Cohort Study
por: Dai, Lili, et al.
Publicado: (2022)

Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
por: Masuda, Chinami, et al.
Publicado: (2017)

Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report
por: Wang, Musen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1u96pnmfagb97nvss68nbhmf2n